NEW YORK, Oct. 8 – Exelixis and Scios said Monday they have agreed to work together to develop a compound library.
Under the terms of the four-year deal, Exelixis of South San Francisco, Calif., will use it s combinatorial chemistry expertise to develop the library of small molecules. In exchange, Scios of Sunnyvale, Calif., will pay Exelixis a per-compound fee and an upfront payment. Exact figures were not released.
Both companies will have the right to use the compound in its own drug discovery program, including in deals with third parties.
"This collaboration will expand Scios' capability to develop cutting-edge therapeutics for inflammatory and cardiovascular diseases," George Schreiner, chief scientific officer at Scios, said in a statement. "The compounds from this collaboration will add to our small molecule technology platform focused on kinase inhibitors."
Geoffrey Duyk, chief scientific officer of Exelixis, said: "These relationships subsidize the cost of generating our large chemical libraries while providing our partners with high quality, cost-effective compounds.”
“This year alone we have screened over 15 assays, and are on track to identify our first development compound by the end of the year," Duyk said.
Scios uses computational and medicinal chemistry to identify new disease targets in its effort to develop new treatments for cardiovascular and inflammatory disease.
Exelixis has developed technologies designed to conduct comparative genomics and to develop model systems for better understanding disease.